Wird geladen...
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK are the most commonly altered oncogenic pathways in solid malignancies. There has been a lot of enthusiasm to develop inhibitors to these pathways for cancer therapy. Unfortunately, the antitumor activities of single-agent therapies have generally been disappointing...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Med Oncol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406912/ https://ncbi.nlm.nih.gov/pubmed/26673580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015571111 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|